Human Endometrial Stromal Cell Differentiation is Stimulated by PPARβ/δ Activation: New Targets for Infertility?

J Clin Endocrinol Metab. 2020 Sep 1;105(9):2983-2995. doi: 10.1210/clinem/dgaa413.

Abstract

Context: Implantation is a reproductive bottleneck in women, regulated by fluctuations in ovarian steroid hormone concentrations. However, other nuclear receptor ligands are modifiers of endometrial differentiation leading to successful pregnancy. In the present study we analyzed the effects of peroxisome-proliferator-activated receptor β/δ (PPARβ/δ) activation on established cellular biomarkers of human endometrial differentiation (decidualization).

Objective: The objective of this work is to test the effects of PPARβ/δ ligation on human endometrial cell differentiation.

Design: Isolated primary human endometrial stromal cells (ESCs) were treated with synthetic (GW0742) or natural (all trans-retinoic acid, RA) ligands of PPARβ/δ, and also with receptor antagonists (GSK0660, PT-S58, and ST247) in the absence or presence of decidualizing hormones (10 nM estradiol, 100 nM progesterone, and 0.5 mM dibutyryl cAMP [3',5'-cyclic adenosine 5'-monophosphate]). In some cases interleukin (IL)-1β was used as an inflammatory stimulus. Time course and dose-response relationships were evaluated to determine effects on panels of well characterized in vitro biomarkers of decidualization.

Results: PPARβ/δ, along with estrogen receptor α (ERα) and PR-A and PR-B, were expressed in human endometrial tissue and isolated ESCs. GW0742 treatment enhanced hormone-mediated ESC decidualization in vitro as manifested by upregulation of prolactin, insulin-like growth factor-binding protein 1, IL-11, and vascular endothelial growth factor (VEGF) secretion and also increased expression of ERα, PR-A and PR-B, and connexin 43 (Cx43). RA treatment also increased VEGF, ERα, PR-A, and PR-B and an active, nonphosphorylated isoform of Cx43. IL-1β and PPARβ/δ antagonists inhibited biomarkers of endometrial differentiation.

Conclusion: Ligands that activate PPARβ/δ augment the in vitro expression of biomarkers of ESC decidualization. By contrast, PPARβ/δ antagonists impaired decidualization markers. Drugs activating these receptors may have therapeutic benefits for embryonic implantation.

Keywords: decidualization; fatty acids; nuclear receptors; retinoic acid; uterus.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Cell Differentiation / drug effects
  • Cell Differentiation / genetics
  • Cells, Cultured
  • Decidua / drug effects
  • Decidua / physiology
  • Endometrium / cytology
  • Endometrium / drug effects*
  • Endometrium / physiology
  • Female
  • Humans
  • Infertility, Female / drug therapy
  • Ligands
  • Molecular Targeted Therapy / methods
  • Molecular Targeted Therapy / trends
  • PPAR delta / agonists*
  • PPAR delta / antagonists & inhibitors
  • PPAR delta / metabolism
  • PPAR-beta / agonists*
  • PPAR-beta / antagonists & inhibitors
  • PPAR-beta / metabolism
  • Stromal Cells / drug effects*
  • Stromal Cells / physiology
  • Sulfones / pharmacology
  • Thiazoles / pharmacology*
  • Thiophenes / pharmacology
  • Up-Regulation / drug effects

Substances

  • GSK0660
  • Ligands
  • PPAR delta
  • PPAR-beta
  • Sulfones
  • Thiazoles
  • Thiophenes
  • (4-(((2-(3-fluoro-4-(trifluoromethyl)phenyl)-4-methyl-1,3-thiazol-5-yl)methyl)sulfanyl)-2-methylphenoxy)acetic acid